These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 10870124)

  • 41. Treatment of Ph1-positive chronic myelogenous leukemia in children: comparison between allogeneic bone marrow transplantation and conventional chemotherapy. Spanish Working Party for BMT in Children (GETMON).
    Muñoz A; Bureo E; Ortega JJ; Richard C; Olivé T; Maldonado MS; Madero L; Díaz MA
    Haematologica; 1998 Nov; 83(11):981-4. PubMed ID: 9864916
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
    Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
    Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia.
    Amabile M; Giannini B; Testoni N; Montefusco V; Rosti G; Zardini C; Terragna C; Buonamici S; Ottaviani E; Soverini S; Fiacchini M; Bassi S; de Vivo A; Trabacchi E; Saglio G; Pane F; Baccarani M; Tura S; Martinelli G
    Haematologica; 2001 Mar; 86(3):252-9. PubMed ID: 11255271
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of graft-versus-host disease on the eradication of minimal residual leukemia detected by polymerase chain reaction in chronic myeloid leukemia patients after bone marrow transplantation.
    Arnold R; Janssen JW; Heinze B; Bunjes D; Hertenstein B; Wiesneth M; Kubanek B; Heimpel H; Bartram CR
    Leukemia; 1993 May; 7(5):747-51. PubMed ID: 8483329
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
    Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
    Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Minimal residual disease in bone marrow transplant recipients with chronic myeloid leukemia.
    Xu WM; Piao XH; Addy L; Jamal M; Minden MD; Messner HA
    Bone Marrow Transplant; 1994 Aug; 14(2):299-306. PubMed ID: 7994246
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia.
    Arpinati M; Tolomelli G; Bochicchio MT; Castagnetti F; Amabile M; Bandini G; Bonifazi F; Stanzani M; Rosti G; Martinelli G; Baccarani M
    Biol Blood Marrow Transplant; 2013 May; 19(5):735-40. PubMed ID: 23333776
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Persistent donor chimaerism is consistent with disease-free survival following BMT for chronic myeloid leukaemia.
    Gardiner N; Lawler M; O'Riordan J; DeArce M; Humphries P; McCann SR
    Bone Marrow Transplant; 1997 Aug; 20(3):235-41. PubMed ID: 9257892
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
    Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S
    Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Fluctuating molecular remission in patients with chronic myeloid leukemia with long term complete cytogenetic response after alpha interferon treatment].
    Casado LF; Picó M; Gómez C; Ferro MT; Fernández-Rañada JM; Steegmann JL
    Med Clin (Barc); 1997 Sep; 109(7):251-5. PubMed ID: 9333689
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expression of bcr-abl fusion transcripts following bone marrow transplantation for Philadelphia chromosome-positive leukemia.
    Kohler S; Galili N; Sklar JL; Donlon TA; Blume KG; Cleary ML
    Leukemia; 1990 Aug; 4(8):541-7. PubMed ID: 2201832
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response.
    Qin YZ; Liu YR; Zhu HH; Li JL; Ruan GR; Zhang Y; Jiang Q; Jiang H; Li LD; Chang Y; Huang XJ; Chen SS
    Int J Lab Hematol; 2008 Aug; 30(4):317-23. PubMed ID: 18665830
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BCR-ABL transcripts detected by polymerase chain reaction (PCR) after allogenic BMT for CML: analysis of 32 longterm disease free patients.
    Guerrasio A; Zaccaria A; Rosso C; Scaravaglio P; Rege Cambrin G; Bertolli VG; Saglio G; Tassinari A; Testoni N; Rosti G
    Bone Marrow Transplant; 1991; 7 Suppl 2():22. PubMed ID: 1878699
    [No Abstract]   [Full Text] [Related]  

  • 56. Estimations of BCR-ABL/ABL transcripts by quantitative PCR in chronic myeloid leukaemia after allogeneic bone marrow transplantation and donor lymphocyte infusion.
    Otazú IB; Tavares Rde C; Hassan R; Zalcberg I; Tabak DG; Seuánez HN
    Leuk Res; 2002 Feb; 26(2):129-41. PubMed ID: 11755463
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
    Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
    Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
    Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
    Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
    Przepiorka D; Khouri I; Thall P; Mehra R; Lee MS; Ippoliti C; Giralt S; Gajewski J; van Besien K; Andersson B; Körbling M; Deisseroth AB; Champlin R
    Bone Marrow Transplant; 1999 May; 23(10):977-81. PubMed ID: 10373061
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The onset of CML in blastic crisis: molecular features.
    Gregorini A; Filippetti A; Luchetti F; Walker A; Lillington DM; Papa S; Valentini M
    J Biol Regul Homeost Agents; 1997; 11(3):111-4. PubMed ID: 9498160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.